Q32 Bio to Participate in Upcoming September Investor Conferences

Q32 Bio (Nasdaq: QTTB), a clinical-stage biotech focused on alopecia areata and other autoimmune and inflammatory diseases, will participate in three September 2026 investor conferences.

Rhea-AI Summary

Q32 Bio (Nasdaq: QTTB), a clinical-stage biotech focused on alopecia areata and other autoimmune and inflammatory diseases, will participate in three September 2026 investor conferences. Management plans fireside chats at the Wells Fargo Healthcare Conference in Boston on September 8, the Cantor Global Healthcare Conference in New York on September 9, and the Morgan Stanley Global Healthcare Conference in New York on September 15.

Webcasts of each presentation will be available on the Events and Presentations page of Q32 Bio’s website, with replays accessible for 90 days. Q32 Bio is advancing bempikibart (ADX-914), an anti-IL-7Rα antibody, in an ongoing Phase 2 program in alopecia areata.

Argus Sep 1 session 4 alerts

-3.60% close to close 2.1x rel. volume Open Argus

Details

News Market Reaction – QTTB

$424.51M Market Cap

On Sep 1, the day this news came out, QTTB closed 3.60% below the previous close. Our momentum scanner recorded 4 alerts for this stock that day. Relative volume reached 2.1x the daily average during tracking.

Data tracked by StockTitan Argus for the Sep 1 session.

Key Figures

Wells Fargo conference date: September 8, 2026 Wells Fargo presentation time: 3:45 p.m. E.T. Cantor conference date: September 9, 2026 +5 more

Wells Fargo conference date

September 8, 2026

21st Annual Healthcare Conference

Wells Fargo presentation time

3:45 p.m. E.T.

Fireside chat presentation

Cantor conference date

September 9, 2026

Global Healthcare Conference 2026

Cantor presentation time

3:55 p.m. E.T.

Fireside chat presentation

Morgan Stanley conference date

September 15, 2026

24th Annual Global Healthcare Conference

Morgan Stanley presentation time

11:30 a.m. E.T.

Fireside chat presentation

U.S. alopecia areata population

700,000 people

People living with alopecia areata in the United States

Trial phase

Phase 2

Ongoing bempikibart program for alopecia areata

Historical Context

5 past events · Latest: Aug 05

5 events

1. Aug 05

   Second-quarter earnings

   24h Move

   +2.1%

   Positive SIGNAL-AA data accompanied Q2 results and a corporate update.

2. Jul 14

   Public offering pricing

   24h Move

   -14.9%

   The company priced a $200 million offering of shares and pre-funded warrants.

3. Jul 13

   Proposed public offering

   24h Move

   -13.7%

   Q32 Bio proposed a $200 million offering subject to market conditions.

4. Jul 13

   Phase 2 clinical data

   24h Move

   +90.7%

   SIGNAL-AA data showed a 35.3% mean SALT score reduction at Week 36.

5. Jul 10

   Clinical data scheduling

   24h Move

   +90.7%

   The company scheduled release of SIGNAL-AA 36-week topline results.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

alopecia areata, anti-il-7rα antibody, il-7, tslp pathways

4 terms

alopecia areata medical

"therapies for alopecia areata ("AA") and other autoimmune"

Alopecia areata is an autoimmune condition in which the body's immune system mistakenly attacks hair follicles, causing round patches of hair loss on the scalp or body; severity ranges from small spots to widespread baldness. Investors watch it because successful treatments, clinical trial results, regulatory approvals, or shifts in prevalence can create or shrink markets for drugs and therapies, affecting the value of companies developing remedies—think of it as demand risk and regulatory risk for hair-loss products.

anti-il-7rα antibody medical

"a fully human anti-IL-7Rα antibody that re-regulates adaptive"

A monoclonal antibody that binds the alpha chain of the interleukin‑7 receptor (IL‑7Rα) on immune cells, blocking IL‑7 signaling that helps certain white blood cells grow and survive. Think of it like a key that fits the receptor’s lock to shut off a specific immune signal; it matters to investors because such drugs are studied as treatments for autoimmune diseases and some cancers and can drive clinical, regulatory, and commercial value.

il-7 medical

"The IL-7 and TSLP pathways have been genetically"

Interleukin-7 (IL-7) is a naturally occurring protein called a cytokine that helps regulate the growth, survival, and function of certain white blood cells, especially T cells. For investors, IL-7 matters because drugs or tests that raise, block, or measure this signal are central to treatments and diagnostics in immune-related diseases and cancer, so developments involving IL-7 can affect biotech valuations much like a key ingredient affects the performance of a recipe.

tslp pathways medical

"The IL-7 and TSLP pathways have been genetically"

TSLP pathways are the chain of biological signals triggered by the protein thymic stromal lymphopoietin (TSLP) that instructs immune cells to start and amplify certain allergic and inflammatory responses. Think of TSLP as a fire alarm that alerts and guides immune ‘first responders’ toward type‑2 inflammation seen in conditions like asthma and eczema. Investors encounter the term because many drugs and diagnostics aim at these pathways, so progress or setbacks in targeting them can affect biotech valuations and clinical pipelines.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

WALTHAM, Mass., Sept. 1, 2026 /PRNewswire/ -- Q32 Bio Inc. (Nasdaq: QTTB) ("Q32 Bio"), a clinical stage biotechnology company focused on developing innovative therapies for alopecia areata ("AA") and other autoimmune and inflammatory diseases, today announced that management will participate in three upcoming investor conferences in September:

Wells Fargo 21st Annual Healthcare Conference
Date: Tuesday, September 8, 2026
Fireside Chat Presentation Time: 3:45 p.m. E.T.
Location: Boston, MA

Cantor Global Healthcare Conference 2026
Date: Wednesday, September 9, 2026
Fireside Chat Presentation Time: 3:55 p.m. E.T.
Location: New York, NY

Morgan Stanley 24th Annual Global Healthcare Conference
Date: Tuesday, September 15, 2026
Fireside Chat Presentation Time: 11:30 a.m. E.T.
Location: New York, NY

A webcast of each presentation will be available on the Events and Presentations page of Q32 Bio's website at www.q32bio.com. Archived replays will be available for 90 days following each event.

About Q32 Bio

Q32 Bio is a clinical stage biotechnology company whose science targets potent regulators of the adaptive immune system to re-balance immunity and is focused on developing innovative therapies for alopecia areata and other autoimmune and inflammatory diseases. About 700,000 people in the United States live with alopecia areata¹, a disease which has a life-altering impact on patients and limited current treatment options. Q32 Bio is advancing bempikibart (ADX-914), a fully human anti-IL-7Rα antibody that re-regulates adaptive immune function, for the treatment of alopecia areata in an ongoing Phase 2 program. The IL-7 and TSLP pathways have been genetically and biologically implicated in driving several T cell-mediated pathological processes in numerous autoimmune diseases.

For more information, visit www.Q32Bio.com.

¹National Alopecia Areata Foundation

Availability of Other Information About Q32 Bio

Investors and others should note that Q32 Bio communicates with its investors and the public using its website www.Q32Bio.com, including, but not limited to, Q32 Bio's disclosures, investor presentations and FAQs, Securities and Exchange Commission (the "SEC") filings, press releases, public conference call transcripts and webcast transcripts, as well as on X (formerly Twitter) and LinkedIn. The information that Q32 Bio posts on its website or on X or LinkedIn could be deemed to be material information. As a result, Q32 Bio encourages investors, the media and others interested to review the information that it posts there on a regular basis. The contents of Q32 Bio's website or social media shall not be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended.

Contacts:
Investors: Brendan Burns
Argot Partners
212.600.1902
Q32Bio@argotpartners.com

Media: David Rosen
Argot Partners
646.461.6387
david.rosen@argotpartners.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/q32-bio-to-participate-in-upcoming-september-investor-conferences-302865342.html

SOURCE Q32 Bio

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When will Q32 Bio (QTTB) present at the Wells Fargo 21st Annual Healthcare Conference in 2026?

Q32 Bio will present at the Wells Fargo 21st Annual Healthcare Conference on Tuesday, September 8, 2026, at 3:45 p.m. E.T. in Boston, Massachusetts. According to Q32 Bio, this appearance will be in a fireside chat format for investors.

What are the dates and times of Q32 Bio (QTTB) presentations at the 2026 Cantor and Morgan Stanley healthcare conferences?

Q32 Bio will present at the Cantor Global Healthcare Conference on Wednesday, September 9, 2026, at 3:55 p.m. E.T. and at the Morgan Stanley Global Healthcare Conference on Tuesday, September 15, 2026, at 11:30 a.m. E.T. in New York, according to Q32 Bio.

How can investors access the Q32 Bio (QTTB) September 2026 investor conference webcasts?

Investors can access Q32 Bio’s September 2026 conference webcasts via the Events and Presentations page on the company’s website. According to Q32 Bio, archived replays of each fireside chat will be available for 90 days following the respective events.

What does Q32 Bio (QTTB) do and what diseases is it targeting?

Q32 Bio is a clinical-stage biotechnology company focused on autoimmune and inflammatory diseases, including alopecia areata. According to Q32 Bio, its science targets regulators of the adaptive immune system to re-balance immunity, aiming to address conditions with limited current treatment options.

What is bempikibart (ADX-914) being developed by Q32 Bio (QTTB) and what stage is it in?

Bempikibart (ADX-914) is a fully human anti-IL-7Rα antibody being developed by Q32 Bio. According to Q32 Bio, it is in an ongoing Phase 2 program for alopecia areata and targets IL-7 and TSLP pathways implicated in T cell-mediated autoimmune diseases.

How many people in the United States are affected by alopecia areata, the focus of Q32 Bio (QTTB)?

According to Q32 Bio, about 700,000 people in the United States live with alopecia areata. The company notes that this disease has a life-altering impact on patients and currently offers limited treatment options, which underpins its therapeutic development focus.